NasdaqGS - Delayed Quote • USD
Cogent Biosciences, Inc. (COGT)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 4:54 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 10 | 9 |
| Avg. Estimate | -0.51 | -0.49 | -2 | -1.99 |
| Low Estimate | -0.59 | -0.59 | -2.42 | -2.7 |
| High Estimate | -0.4 | -0.33 | -1.41 | -1.39 |
| Year Ago EPS | -0.54 | -0.59 | -2.42 | -2 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | -- | -- | -- | 1.32M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 10.6M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.57 | -0.54 | -0.5 | -0.56 |
| EPS Actual | -0.54 | -0.59 | -0.64 | -0.63 |
| Difference | 0.03 | -0.05 | -0.14 | -0.07 |
| Surprise % | 5.30% | -9.30% | -28.00% | -12.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.51 | -0.49 | -2 | -1.99 |
| 7 Days Ago | -0.51 | -0.49 | -2 | -1.99 |
| 30 Days Ago | -0.51 | -0.49 | -2 | -1.99 |
| 60 Days Ago | -0.53 | -0.52 | -2.11 | -1.89 |
| 90 Days Ago | -0.53 | -0.51 | -2.09 | -1.89 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | COGT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 5.60% | -- | -- | 1.60% |
| Next Qtr. | 16.90% | -- | -- | 10.50% |
| Current Year | 17.40% | -- | -- | 5.20% |
| Next Year | 0.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | JP Morgan: Overweight to Overweight | 2/27/2024 |
| Maintains | Citigroup: Buy to Buy | 2/26/2024 |
| Downgrade | Baird: Outperform to Neutral | 2/26/2024 |
| Reiterates | Needham: Buy to Buy | 2/26/2024 |
| Maintains | Wedbush: Neutral to Neutral | 2/23/2024 |
| Reiterates | Needham: Buy to Buy | 2/12/2024 |
Related Tickers
AGIO Agios Pharmaceuticals, Inc.
29.53
+0.34%
ACLX Arcellx, Inc.
51.65
-5.23%
DNTH Dianthus Therapeutics, Inc.
23.25
-1.61%
KURA Kura Oncology, Inc.
17.53
-0.85%
PEPG PepGen Inc.
10.54
-11.06%
ALEC Alector, Inc.
5.09
0.00%
IGMS IGM Biosciences, Inc.
7.20
-2.83%
IMCR Immunocore Holdings plc
55.68
+1.72%
FOLD Amicus Therapeutics, Inc.
10.61
+2.71%
CRGX CARGO Therapeutics, Inc.
19.19
+0.47%